Brainstorm Cell Therapeutics Inc
NASDAQ:BCLI

Watchlist Manager
Brainstorm Cell Therapeutics Inc Logo
Brainstorm Cell Therapeutics Inc
NASDAQ:BCLI
Watchlist
Price: 1.31 USD 14.91% Market Closed
Market Cap: 10.4m USD

Relative Value

There is not enough data to reliably calculate the relative value of BCLI.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

BCLI Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.3
vs History
vs Industry
Median 3Y
-3.3
Median 5Y
-59
Industry
23.3
Forward
-0.8
vs History
vs Industry
Median 3Y
-2.6
Median 5Y
-62.6
Industry
19.8
vs History
vs Industry
Median 3Y
-2.6
Median 5Y
-62.4
Industry
22.6
vs History
vs Industry
Median 3Y
-4.3
Median 5Y
-1.2
Industry
2.7
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.6
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.4
vs History
vs Industry
Median 3Y
-2.7
Median 5Y
-59.1
Industry
4.7
Forward
-0.6
vs History
vs Industry
Median 3Y
-2.7
Median 5Y
-58.6
Industry
4.8
Forward
-0.6
vs History
vs Industry
Median 3Y
-2.6
Median 5Y
-62.4
Industry
5.3
vs History
vs Industry
Median 3Y
-2.6
Median 5Y
-62.4
Industry
3.8
vs History
vs Industry
4
Median 3Y
-7.4
Median 5Y
-1.8
Industry
5

Multiples Across Competitors

BCLI Competitors Multiples
Brainstorm Cell Therapeutics Inc Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Brainstorm Cell Therapeutics Inc
NASDAQ:BCLI
10.4m USD 0 -0.9 -0.8 -0.8
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 841 650.5 -160 844.3 -195 316.3 -193 087.6
US
Abbvie Inc
NYSE:ABBV
336.5B USD 5.9 81 15.4 22.8
US
Amgen Inc
NASDAQ:AMGN
159.5B USD 4.7 26.9 14.4 23.8
US
Gilead Sciences Inc
NASDAQ:GILD
140.2B USD 4.9 23.5 10.2 14.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
122.7B USD 11.1 -124 26.4 27.7
US
Epizyme Inc
F:EPE
94.1B EUR 2 081.7 -531.2 -578.4 -563
AU
CSL Ltd
ASX:CSL
118B AUD 5.1 28 17.3 21.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
59.6B USD 4.2 13.3 11.8 13.3
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.5 -66.3 -59.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
41.5B USD 17.7 -154 -690.7 -346.1
P/S Multiple
Revenue Growth P/S to Growth
US
Brainstorm Cell Therapeutics Inc
NASDAQ:BCLI
Average P/S: 3 384 380.6
Not Available
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 841 650.5
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.9
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.7
4%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.9
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
11.1
10%
1.1
US
E
Epizyme Inc
F:EPE
2 081.7
N/A N/A
AU
CSL Ltd
ASX:CSL
5.1
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.2
4%
1.1
US
S
Seagen Inc
F:SGT
20.1
30%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
17.7
29%
0.6
P/E Multiple
Earnings Growth PEG
US
Brainstorm Cell Therapeutics Inc
NASDAQ:BCLI
Average P/E: 34.5
Negative Multiple: -0.9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 844.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
81
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
26.9
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
23.5
188%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -124 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -531.2 N/A N/A
AU
CSL Ltd
ASX:CSL
28
16%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.3
7%
1.9
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.5 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -154 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Brainstorm Cell Therapeutics Inc
NASDAQ:BCLI
Average EV/EBITDA: 15.9
Negative Multiple: -0.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 316.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.4
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.4
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.4
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -578.4 N/A N/A
AU
CSL Ltd
ASX:CSL
17.3
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.8
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.3 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -690.7 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Brainstorm Cell Therapeutics Inc
NASDAQ:BCLI
Average EV/EBIT: 20.5
Negative Multiple: -0.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -193 087.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.8
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.8
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
14.1
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.7
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -563 N/A N/A
AU
CSL Ltd
ASX:CSL
21.6
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.3
11%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.8 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -346.1 N/A N/A